The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EMN 2021 | Pomalidomide plus dexamethasone for R/R multiple myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, gives an overview of the results of a retrospective analysis of pomalidomide and dexamethasone therapy for patients with relapsed/refractory (R/R) multiple myeloma. The study analyzed data from 57 patients with R/R multiple myeloma who were treated with pomalidomide plus dexamethasone. The study found that pomalidomide was well tolerated with an overall response rate of 47.3%. Five patients achieved a complete response and 11 patients achieved a very good partial response. The median overall survival from the start of pomalidomide therapy was nine months. This interview took place during the 2021 European Myeloma Network (EMN) congress.
